What Is BPC-157? Definition and What Research Reports

Plain definition

BPC-157 is the name given to a laboratory-made chain of 15 amino acids — a pentadecapeptide — whose sequence was taken from a larger protein fragment described in human gastric juice. The initials stand for "Body Protection Compound," a name given by the research group that first characterised it, and "157" refers to the specific fragment number used in that early work. In practice, when people write "BPC-157" they are referring to a synthetic peptide studied mainly in animals for its reported effects on tissue repair, and not to an approved medicine that a pharmacy dispenses. A 2025 literature and patent review described BPC-157 as a multifunctional peptide with a wide range of experimental applications and ongoing patent activity (PMID 40005999).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question or any decision involving a medical product.

What BPC-157 is in biochemical terms

Chemically, BPC-157 is a short linear peptide of fifteen residues with no disulfide bridges and no post-translational modifications in its standard synthetic form. Research papers frequently describe it as "stable gastric pentadecapeptide BPC 157," a phrase that appears in the titles of multiple reviews and reflects the claim in that literature that the peptide remained stable in human gastric juice — a property the authors contrasted with many other peptides (PMID 34267654). The spelling varies between papers: "BPC 157" without a hyphen is the form used most often by the original research groups, while "BPC-157" is the more common form online.

Mechanistically, the published reviews do not describe a single receptor. Instead, they discuss several proposed pathways. Reviews of tendon, ligament, muscle and bone work have linked the peptide's reported effects to angiogenic growth factor signalling, including interactions with vascular endothelial growth factor pathways, and have compared it with standard angiogenic growth factors (PMID 29998800). A separate review focused on blood vessels described reported effects on vessel formation and vascular responses (PMID 23782145), and a review of the central nervous system summarised experimental work on neuroprotective and behavioural outcomes in rodents (PMID 34380875). Readers should note these are author summaries of animal experiments, not established human pharmacology.

Regulatory status of the term

BPC-157 is not an approved drug product in the United States or the European Union. There is no marketing authorisation, no approved label, and therefore no official indication, dose or safety profile of the kind that accompanies an approved medicine. Material sold under the name is typically labelled "research use only" (RUO), a designation that signals the substance has not been evaluated for human administration and is not intended for it. Because there is no approved product, any statement about what BPC-157 "does" in people rests on a small number of published human reports plus a much larger animal literature. A 2025 narrative review framed exactly this tension in its title — regeneration or risk — and noted that enthusiasm for musculoskeletal use has outpaced the human evidence base (PMID 40789979). A 2025 systematic review of orthopaedic sports medicine literature reached a similar conclusion about the limited volume of clinical data (PMID 40756949).

How the term is used in peptide research

Within the published literature, "BPC-157" appears most often in three research contexts:

• Gastrointestinal models. The peptide originated from gastric juice research, and reviews continue to place gut healing at the centre of its experimental profile (PMID 29998800).
• Musculoskeletal soft-tissue models. A 2019 review collected animal work on tendon, ligament and muscle healing (PMID 30915550), and a 2011 laboratory study reported that the peptide promoted tendon explant outgrowth, cell survival and cell migration in tendon fibroblast experiments (PMID 21030672).
• Wound, vascular and nervous-system models. Reviews have grouped skin wound healing (PMID 34267654), blood-vessel responses (PMID 23782145) and central nervous system outcomes (PMID 34380875) under the same peptide heading.

Where the term is misused

Several common usages do not match the literature:

1. Treating rodent findings as human findings. The bulk of the cited work is preclinical. A review of striated, smooth and heart muscle summarised animal muscle experiments, not clinical trials (PMID 36551977).
2. Calling it "clinically validated." The 2025 systematic review of orthopaedic sports medicine described the clinical evidence base as limited (PMID 40756949).
3. Using "BPC-157" and "stable gastric pentadecapeptide" as if they were different compounds. They refer to the same peptide; the longer phrase is simply the descriptive name used in many titles (PMID 34267654).
4. Assuming an oral, topical and injected form are interchangeable. Published studies used different routes in different models, and route is part of what a given result describes.

Related terms

What the published literature reports

Animal and laboratory work forms the largest share. The 2011 tendon study reported effects on tendon fibroblast outgrowth, survival and migration in an experimental system (PMID 21030672). The 2019 musculoskeletal review concluded that the accumulated animal data described accelerated soft-tissue healing across several injury models (PMID 30915550). Reviews of wound healing and blood vessels described similar directional findings in their respective models (PMID 34267654, PMID 23782145).

Human reports are far fewer and are small. A 2021 report described intra-articular injection of BPC 157 in patients with multiple types of knee pain and reported symptom outcomes in that series (PMID 34324435). A 2024 pilot study examined symptoms in patients with interstitial cystitis (PMID 39325560). Both were small, non-definitive reports, and researchers in the 2025 narrative review emphasised that human safety data remain sparse (PMID 40789979).

Safety Signals: What Studies Report

The reviews that addressed safety did so cautiously. The 2025 narrative review explicitly weighed reported regenerative findings against unresolved risk, noting the absence of long-term human safety data and the unregulated nature of much of the material circulating outside research settings (PMID 40789979). The 2025 systematic review similarly reported that the available orthopaedic literature did not support firm conclusions about clinical safety or efficacy (PMID 40756949). The 2025 literature and patent review catalogued the breadth of proposed applications while treating them as experimental (PMID 40005999). Nothing in these sources establishes an approved human use.

References

• Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review (Pharmaceuticals, 2025)
• Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain (Alternative Therapies in Health and Medicine, 2021)
• Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing (Cell and Tissue Research, 2019)
• Stable Gastric Pentadecapeptide BPC 157 and Wound Healing (Frontiers in Pharmacology, 2021)
• Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing (Current Reviews in Musculoskeletal Medicine, 2025)
• Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (HSS Journal, 2025)
• BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing (Current Pharmaceutical Design, 2018)
• Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study (Alternative Therapies in Health and Medicine, 2024)
• Pentadecapeptide BPC 157 and the central nervous system (Neural Regeneration Research, 2022)
• BPC 157 and blood vessels (Current Pharmaceutical Design, 2014)
• Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle (Biomedicines, 2022)
• The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration (Journal of Applied Physiology, 2011)